Belite Bio Inc. ADS/$BLTE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Belite Bio Inc. ADS

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Ticker

$BLTE
Primary listing

Industry

Pharmaceuticals

Employees

25

BLTE Metrics

BasicAdvanced
$2.1B
-
-$1.37
-1.48
-

Bulls say / Bears say

Belite Bio's lead candidate, Tinlarebant, received Breakthrough Therapy Designation from the FDA for treating Stargardt disease, indicating strong potential for expedited development and approval. (newsheater.com)
The company successfully completed enrollment in its Phase 3 PHOENIX trial for geographic atrophy, demonstrating progress in its clinical pipeline. (simplywall.st)
Analysts have raised their price targets for Belite Bio, with Maxim Group increasing its target to $110, reflecting confidence in the company's growth prospects. (defenseworld.net)
Belite Bio reported a net loss of $14.3 million in Q1 2025, up from $7.9 million in the same period last year, indicating increasing operational expenses. (stocktitan.net)
Leerink Partners reduced their FY2028 EPS estimate for Belite Bio from $4.60 to $4.40, suggesting tempered expectations for long-term profitability. (etfdailynews.com)
The company's reliance on successful clinical trial outcomes for Tinlarebant poses a risk; any setbacks could negatively impact stock performance. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BLTE

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs